tiprankstipranks
Elevance Health (CH:A58)
:A58
Switzerland Market

Elevance Health (A58) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

A58 Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
11 Buy
6 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A58 Stock 12 Month Forecast

Average Price Target

Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is CHF361.78 with a high forecast of CHF396.18 and a low forecast of CHF319.06. The average price target represents a change from the last price of .
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
Highest Price TargetCHF396.18Average Price TargetCHF361.78Lowest Price TargetCHF319.06
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:A58
Bernstein
Bernstein
CHF396.18
Buy
Reiterated
08/14/26
Bernstein Remains a Buy on Elevance Health (ELV)
Barclays
CHF371.02
Buy
Assigned
07/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)
Morgan Stanley Analyst forecast on CH:A58
Morgan Stanley
Morgan Stanley
CHF327.99
Hold
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on CH:A58
Leerink Partners
Leerink Partners
CHF295.51CHF320.68
Hold
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen
CHF377.51
Buy
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
Truist Financial
Truist Financial
CHF385.63
Buy
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on CH:A58
Jefferies
Jefferies
CHF317.43CHF365.33
Buy
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on CH:A58
Wells Fargo
Wells Fargo
CHF399.43CHF384.01
Buy
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Bank of America Securities Analyst forecast on CH:A58
Bank of America Securities
Bank of America Securities
CHF373.45
Buy
Reiterated
07/16/26
Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals
Robert W. Baird Analyst forecast on CH:A58
Robert W. Baird
Robert W. Baird
CHF268.72CHF319.06
Hold
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on CH:A58
Evercore ISI
Evercore ISI
Hold
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on CH:A58
RBC Capital
RBC Capital
CHF356.4CHF344.22
Hold
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on CH:A58
Goldman Sachs
Goldman Sachs
CHF300.38CHF320.68
Hold
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on CH:A58
Guggenheim
Guggenheim
CHF323.93CHF369.39
Buy
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Mizuho Securities Analyst forecast on CH:A58
Mizuho Securities
Mizuho Securities
CHF377.51CHF381.57
Buy
Reiterated
07/13/26
Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:A58
Bernstein
Bernstein
CHF396.18
Buy
Reiterated
08/14/26
Bernstein Remains a Buy on Elevance Health (ELV)
Barclays
CHF371.02
Buy
Assigned
07/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)
Morgan Stanley Analyst forecast on CH:A58
Morgan Stanley
Morgan Stanley
CHF327.99
Hold
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on CH:A58
Leerink Partners
Leerink Partners
CHF295.51CHF320.68
Hold
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen
CHF377.51
Buy
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
Truist Financial
Truist Financial
CHF385.63
Buy
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on CH:A58
Jefferies
Jefferies
CHF317.43CHF365.33
Buy
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on CH:A58
Wells Fargo
Wells Fargo
CHF399.43CHF384.01
Buy
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Bank of America Securities Analyst forecast on CH:A58
Bank of America Securities
Bank of America Securities
CHF373.45
Buy
Reiterated
07/16/26
Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals
Robert W. Baird Analyst forecast on CH:A58
Robert W. Baird
Robert W. Baird
CHF268.72CHF319.06
Hold
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on CH:A58
Evercore ISI
Evercore ISI
Hold
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on CH:A58
RBC Capital
RBC Capital
CHF356.4CHF344.22
Hold
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on CH:A58
Goldman Sachs
Goldman Sachs
CHF300.38CHF320.68
Hold
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on CH:A58
Guggenheim
Guggenheim
CHF323.93CHF369.39
Buy
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Mizuho Securities Analyst forecast on CH:A58
Mizuho Securities
Mizuho Securities
CHF377.51CHF381.57
Buy
Reiterated
07/13/26
Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
George HillDeutsche Bank
Success Rate
11/18 ratings generated profit
61%
Average Return
+3.62%
Copying George Hill's trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +3.62% per trade.
1 Year
Success Rate
24/30 ratings generated profit
80%
Average Return
+19.55%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.55% per trade.
2 Years
Success Rate
27/30 ratings generated profit
90%
Average Return
+38.79%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +38.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A58 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
25
29
30
27
20
Hold
9
9
9
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
34
38
39
36
28
In the current month, A58 has received 20 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. A58 average Analyst price target in the past 3 months is 361.78.
Each month's total comprises the sum of three months' worth of ratings.

A58 Financial Forecast

A58 Earnings Forecast

Next quarter’s earnings estimate for A58 is CHF3.82 with a range of CHF3.70 to CHF4.44. The previous quarter’s EPS was CHF6.06. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s earnings estimate for A58 is CHF3.82 with a range of CHF3.70 to CHF4.44. The previous quarter’s EPS was CHF6.06. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Sales Forecast

Next quarter’s sales forecast for A58 is CHF40.11B with a range of CHF38.89B to CHF41.49B. The previous quarter’s sales results were CHF41.07B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s sales forecast for A58 is CHF40.11B with a range of CHF38.89B to CHF41.49B. The previous quarter’s sales results were CHF41.07B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Stock Forecast FAQ

What is CH:A58’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 361.78.
    What is CH:A58’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:A58, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Elevance Health a Buy, Sell or Hold?
        Elevance Health has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Elevance Health’s share price target?
          The average share price target for Elevance Health is 361.78. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF396.18 ,and the lowest forecast is CHF319.06. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Elevance Health?
            Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
              How can I buy shares of Elevance Health?
              To buy shares of CH:A58, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.